The FDA approved the use of Novartis' meningococcal conjugate vaccine Menveo to include toddlers and infants 2 months and older. The vaccine provides protection against meningococcal disease related to four strains of Neisseria meningitidis. The expanded approval was based on data from three trials involving more than 8,700 infants.

Related Summaries